Abstract. Cervical cancer (CC) is a common gynecological malignancy in women worldwide. Using an RNA sequencing profile from The Cancer Genome Atlas (TCGA) and the CC patient information, the aim of the present study was to identify potential long non-coding RNA (lncRNA) biomarkers of CC using bioinformatics analysis and building a competing endogenous RNA (ceRNA) co-expression network. Results indicated several CC-specific lncRNAs, which were associated with CC clinical information and selected some of them for validation and evaluated their diagnostic values. Bioinformatics analysis identified 51 CC-specific lncRNAs (fold-change >2 and P<0.05), and 42 of these were included in ceRNA network consisting of lncRNA-miRNA-mRNA interactions. Further analyses revealed that differential expression levels of 19 lncRNAs were significantly associated with different clinical features (P<0.05). A total of 11 key lncRNAs in the ceRNA network for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis to detect their expression levels in 31 pairs of CC clinical samples. The results indicated that 7 lncRNAs were upregulated and 4 lncRNAs were downregulated in CC patients. The fold-changes between the RT-qPCR experiments and the TCGA bioinformatics analyses were the same. Furthermore, the area under the receiver operating characteristic (ROC) curve of four lncRNAs (EMX20S, MEG3, SYS1-DBNDD2 and MIR9-3HG) indicated that their combined use may have a significant diagnostic value in CC (P<0.05). To the best of our knowledge, the present study is the first to have identified CC-specific lncRNAs to construct a ceRNA network and has also provided new insights for further investigation of a lncRNA-associated ceRNA network in CC. In additon, the verification results suggested that the method of bioinformatics analysis and screening of lncRNAs was accurate and reliable. To conclude, the use of multiple lncRNAs may thus improve diagnostic efficacy in CC. In addition, these specific lncRNAs may serve as new candidate biomarkers for clinical diagnosis, classification and prognosis of CC.
Introduction
Cervical cancer (CC) is one of the most lethal cancers with increasing incidence and mortality over the past decades, and is the second most common female malignant disease worilwide (1) . According to the latest world cancer statistics, approximately 529,800 female are diagnosed with CC and approximately 275,100 die worldwide each year, making CC the second fastest growing cancer and a serious threat to women's health (2) . Meanwhile, the age of CC incidence has progressively decreased, which has attracted wide attention. Recent studies have shown that lifestyle, environmental pollution, population aging genetic predisposition, HPV infection and the impact of hormones are the important causes of CC (3) . Although the morbidity and mortality of CC has declined in the past 30 years, the 5-year survival rate of advanced-stage patients still below 40% (4) . Therefore, in order to improve the cure percentage of CC, it is important to understand its molecular mechanism and identify effective diagnostic and prognostic biomarkers.
Long non-coding RNA (lncRNA) is a non-coding RNA more than 200 nucleotides in length (5) . More and more evidence has showed that lncRNAs is an important part of a complex gene regulatory network which regulates gene expression at the epigenetics and transcriptome levels (6) . The lncRNAs are differently expressed in many kinds of cancers (7, 8) , including gastric, lung and ovarian cancer (9) (10) (11) . In addition, abnormal expression of lncRNAs has been related Integrated analysis of long non-coding RNA competing interactions revealed potential biomarkers in cervical cancer: Based on a public database to metastasis, recurrence, and prognosis of various human tumors (12) . More importantly, Compared with protein coding mRNAs and miRNA, lncRNAs have greater tissue specificity (13) . Thus, discovery of differentially expressed lncRNAs in CC may be important for the diagnosis and the identifications for this disease. Recently, the hypothesis of competing endogenous RNAs (ceRNAs) has suggested that RNA transcripts interact via miRNA response elements. Increasing evidences indicates that lncRNAs, mRNAs and pseudogene acting as ceRNAs can be regulated by MREs and play key funtions in metastasis, tumorigenesis and progression of tumors (14) . Meanwhile, ceRNA activity also plays an important roles in the transcriptome and increasing evidence has shown that genetic information is closely related to pathological change in most cancers (15) .
HPV infection alone is not be the only factor CC formation. Host genetic variations also play an important roles in the development of CC (16) . With the development of high-throughput gene sequencing technologies and molecular biology methods, we can use these new tools for the discovery and identification of cancer biomarkers (17, 18) . However, studies to date have lacked the integrated analysis of large samples and the sensitivity of CC-specific lncRNAs biomarkers. In addition, small sample studies do not have the statistical power to explain the relationships between abnormal lncRNAs and CC patients' clinical features Recently, The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov) database has collected and provided a large sample size of CC genome sequencing data. The aim of our study was to solve the problem of small sample size and improve the accuracy and reliability of results by using TCGA RNA sequencing data from CC patients to find CC-related lncRNAs. In this study, we collected whole transcriptome RNA sequencing data of 307 CC tissues specimens and six adjacent nontumor tissue specimens through the TCGA database. To the best of our knowledge, our study is the first time to investigate the CC-related lncRNA expression profiles through the use of a large-scale samples RNA sequencing database. Subsequently, the reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to validate part of the bioinformatics analysis results by 31 pairs of newly diagnosed CC clinical samples. This new method of finding CC-related lncRNAs through the ues of ceRNA network can help determine the potential functions of lncRNAs in CC progression and development.
Materials and methods

Patients and samples.
Following the TCGA guidelines, we downloaded RNA sequencing data and clinical pathological information from 307 cases of cervical squamous cell carcinoma (CESC) in the TCGA database (up to Decenber 1, 2016) . Then, we excluded cases without completed analysis data, with a histologic diagnosis that was not CESC, with more than two malignant tumors, and those which had received preoperative chemoradiation. Finally, 289 CC patients remained for analysis based on the above exclusion criteria. From these patients, RNA sequencing data from 289 tumor tissues and six nontumor tissues were obtained. Using the international Federation of Gynecology and Obstetrics (FIGO) staging system, we divided the patients into three groups, FIGO stage I were 158 patients, FIGO stage II, 68 patients; and FIGO stage III-IV, 63 patients.
In addition, 31 tissue specimens (tumor tissues and adjacent normal tissue) were collected between 2016 and 2017 at the Zhongda Hospital of Southeast University (Nanjing, China) form CC patients, aged 23-64 years for RT-qPCR analysis. Tissues specimens were rapidly frozen in RNAlater (Ambion; Thermo Fisher Scientific, Inc., Austin, TX, USA) and were stored in liquid nitrogen for subsequent RNA extraction and RT-qPCR analysis. These 31 patients were diagnosed of CC based on the histopathology and clinical history. All patients signed informed consent, and this study also was approved by the ethics committee of Zhongda Hospital Southeast University.
RNA sequence data collects and analysis. The CESC-RNA sequencing data (level 3) and clinical information were downloaded from TCGA database until December 1, 2016. The TCGA database provides normalized count data for RNA sequencing through the RNASeqV2 system, which contained the lncRNA and mRNA sequencing data. Meanwhile, CESC miRNA sequencing data also were obtained through the TCGA database. Level 3 miRNA sequencing base data were obtained through Illumina HiSeq 2000 miRNA sequencing platforms (Illumina, Inc., San Diego, CA, USA). The RNA sequencing data from these CESC patients tissues specimens had previously been normalized to the TCGA database. We then further analyzed the differentially expressed RNA sequencing data by bioinformatics analysis. The bioinformatics analysis is shown in Fig. 1 .
Functional enrichment of Gene Ontology (GO) and pathway analysis.
We analyzed the biological processes of aberrantly expressed intersection mRNAs through the Database for Annotation, Visualization, and Integrated Discovery (DAVID) (http://david.abcc.ncifcrf.gov/), which used GO database to investigate the potential functions of these aberrantly expressed intersection mRNAs (19) . The potential functions of mRNAs participating in the pathways were then analyzed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database.
Construction of ceRNA network. We made use of the theory in which lncRNAs regulate miRNA by binding and sequestering them and miRNAs in turn regulate mRNAs via lncRNA-miRNA-mRNA interactions in the competitive endogenous RNA network (20) . Therefore, we selected the abnormally expressed lncRNA, miRNA, and mRNA in the intersection of three groups based on fold-change >2.0 and P<0.05. Next, we used miRanda (http://www.microrna.org) to predict the miRNA targets and investigate lncRNA-miRNA relationships. Meanwhile, Target scan (http://www.targetscan.org/) and miRbase targets (http://mirdb.org) were used to predict miRNA target genes. Finally, we combined the differentially expressed data from TCGA with the predicted targets of miRNAs to select and the results of miRNAs that predicted target lncRNAs and mRNAs to select commonly regulated lncRNAs and mRNAs. In accordance with the principle of negative regulation of ceRNA, we select the most negative regulated miRNA, lncRNAs and mRNA to build the ceRNA regulatory network, using Cytoscape version 3.0 to construct it (21) . Fig. 1 shows a flow chart outlining the steps used to bulid the ceRNA network.
Association analysis between CC specific lncRNAs and clinical features. We chose the key lncRNAs to be included in the ceRNA network according to the comprehensively bioinformatics analysis of the CC RNA sequencing data in TCGA. In the next step, we further analyzed the relationships between CC-specific lncRNAs and patients clinical features including race, pathological stage, tumor grade, TNM stage, FIGO stage and HPV infection. Subsequently, we chose several of the key lncRNAs in the ceRNA network and validate the accuracy and reliability of results from the bioinformatics analysis using RT-qPCR to analyze 31 newly diagnosed CC patients.
Extraction of total RNA f rom clinical samples and RT-qPCR verification of bioinformatics results.
We random selected 17 key lncRNAs associated with CC patients clinical features that had high association scores in the above bioinformatics ceRNA network. Then, we utilized RT-qPCR to analyzed the actual expression levels of these lncRNAs in 31 newly diagnosed CC patients. We chose GAPDH as the endogenous standard to confirm the accuracy and reliability of our bioinformatics analysis. Total RNA were isolated from tissues specimens of the CC patients using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol, and the purity of the isolated RNA was assessed using NanoDrop 2000 spectrometer (Thermo Fisher Scientific, Inc.). Reverse transcription reactions and RT-qPCR were performed according to the manufacturer's protocol, using the reverse transcription system and qPCR Master Mix kit (Promega Corporation, Madison, WI, USA) as well as the Step One Plus™ PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.) to detect the expression levels of lncRNAs. All the primers were produced by Generay Biotech Co., Ltd. (Shanghai, China). The RT-qPCR results were calculated using the 2 -ΔΔCq method (22) Statistical analysis. Data analysis was performed using SPSS software version 24.0 (IBM Corp., Armonk, NY, USA). The final results were expressed as mean ± standard deviation. Student's t-test were used to compare the fold-change between groups of sequencing data. In all cases, P<0.05 was considered to indicate a statistically significant difference. In addition, we used receiver operating characteristic (ROC) curves and the area under the curve (AUC) to judge the diagnostic value of 6 lncRNAs in CC patients.
Results
Cancer specific lncRNAs in CC. Base on TCGA database 'Level 3' CESC RNA-Sequencing (RNA-Seq) data, we observed that 71 lncRNAs were abnormality expressed in 289 CC patients tumor tissues compared to 6 adjacent normal cervical tissues with a fold-change >2 and P<0.05.
Subsequently, we obtained abnormally expressed lncRNAs from 68 FIGO stage I CC tissues, 68 FIGO stage II tissues, and 71 FIGO stage III-IV tissues when compared to adjacent normal cervical tissues. In order to further narrow the scope of bioinformatics analysis and improve the accuracy, we chosed 51 lncRNAs that were common to all three groups (Fig. 2 ). There were 42 lncRNAs (13 upregulated; 29 downregulated; Table I ) involved in the ceRNA network in these 51 lncRNAs.
Functional enrichment analysis. The function of differentially expressed mRNAs in CC was analyzed at the GO and KEGG pathway levels by DAVID Bioinformatics tool. There were 2,650 differentially expressed mRNAs between CC tumor tissues and adjacent normal cervical tissues in FIGO stage form the TCGA. Focused on these differentially expressed genes, there were 2,484 differentially expressed mRNAs between CC tumor tissues and adjacent normal cervical tissues in FIGO stage I; 2,392 differentially expressed mRNAs in FIGO stage II and 2,650 differentially expressed mRNAs in FIGO stage III-IV. We analyzed the enrichment of these 2,057 differentially expressed mRNAs in the GO database (Fig. 2) , then analyzed the upregulated and downregulated mRNAs. We found that the highest enriched GO terms were mitotic cell cycle, cell division, DNA replication and apoptotic process in upregulated transcripts. and cell adhesion, signal transduction, transcription and DNA-dependent in downregulated transcripts (Fig. 3 ). There were 87 pathways corresponded to upregulated transcripts by pathway analysis; the main enriched pathway was the Cell cycle. In the 109 pathways in the downregulated transcripts; the main enriched pathway was cGMP-PKG signaling pathway. We separately described the top 20 KEGG pathways, including downregulated and upregulated genes (Fig. 4) . Among these pathways, the p53 signaling pathway, viral carcinogenesis, PI3K-Akt signaling pathway, Ras signaling pathway, MAPK signaling pathway, mTOR signaling pathway and Rap1 signaling pathway may be related to development and prognosis of cancer. In addition, other pathways such as cGMP-PKG signaling pathway, Cell cycle and leukocyte transendothelial migration were also associated with cancer pathways (Table II and Fig. 4) .
The ceRNA network. In our study, we found 72 differentially expressed miRNAs with the fold-change >2 and P<0.05. We picked out 58 intersection miRNAs from these 72 miRNAs by bioinformatics analysis of the FIGO stage (Fig. 2B) . and determined if these interacting miRNAs had a target relationship with any of the 51 CC-specific lncRNAs. We predicted 56 miRNAs targeted 49 key lncRNAs by miRcode (http://www.mircode.org/) (23) (Table III) in the ceRNAs network. Then, mRNA targeted by miRNAs, we found 49 specific miRNAs associated with 97 mRNAs (Tables II and IV) . Some mRNAs targeted cancer-associated genes, including BCL2, MAP3K3, AKT3, E2F3.
Based on our bioinformatics analysis, we investigate the relationship between lncRNAs and mRNAs potential linked by miRNAs that were identified in Tables II and III , and build the ceRNA (lncRNA-miRNA-mRNA) network. There were 72 differentially expressed miRNAs identified in CC tissues samples, among which were the 58 intersecting miRNAs (Fig. 2B) . We then used the MREs principle to find the relationships between these 58 miRNAs and 51 CC-specific lncRNAs, and detected the potential MREs by starBase. The results showed that there were 49 specific miRNAs and 42 specific lncRNAs with potential regulatory relationships. We then used Cytoscape 3.0 to build the ceRNA network based on data from Tables III and IV. hsa-miR-106b-5p, hsa-miR-15b-5p, hsa-miR-93-5p AMZ2P1 hsa-miR-183-5p ASMTL-AS1 hsa-miR-30b-5p ATP1A1-AS1 hsa-miR-106b-5p, hsa-miR-183-5p CDKN2B-AS1 hsa-miR-140-5p, hsa-miR-195-5p DDX12P hsa-miR-10b-3p, hsa-miR-139-5p, hsa-miR-140-3p, hsa-miR-145-5p, hsa-miR-497-5p EMX2OS hsa-miR-106b-5p, hsa-miR-141-5p, hsa-miR-16-5p, hsa-miR-183-5p, hsa-miR-205-5p, hsa-miR-21-3p, hsa-miR-93-5p EP400NL hsa-miR-140-3p EPB41L4A-AS1 hsa-miR-141-5p, hsa-miR-15b-5p, hsa-miR-16-5p FAM66C hsa-miR-15b-5p, hsa-miR-16-5p, hsa-miR-185-5p FLJ10038 hsa-miR-106b-5p, hsa-miR-183-5p, hsa-miR-200b-3p, hsa-miR-32-5p, hsa-miR-429 FTX hsa-miR-185-5p GEMIN8P4 hsa-miR-143-3p GOLGA2P10 hsa-miR-10b-5p, hsa-miR-133a-3p, hsa-miR-140-3p, hsa-miR-195-5p, hsa-miR-320a, hsa-miR-497-5p GOLGA2P5 hsa-miR-132-3p, hsa-miR-133a-3p, hsa-miR-139-5p, hsa-miR-328-3p ILF3-AS1 hsa-miR-106b-5p, hsa-miR-93-5p INE2 hsa-miR-106b-5p, hsa-miR-93-5p LINC00312 hsa-miR-15b-5p, hsa-miR-16-5p, hsa-miR-21-3p LINC00341 hsa-miR-200a-3p, hsa-miR-205-5p, hsa-miR-425-5p LINC00467 hsa-miR-132-3p, hsa-miR-133a-3p LINC00663 hsa-miR-106b-5p, hsa-miR-141-3p, hsa-miR-15b-5p, hsa-miR-200a-3p, hsa-miR-93-5p LINC00950 hsa-miR-141-3p, hsa-miR-141-5p, hsa-miR-200b-3p, hsa-miR-200c-3p, hsa-miR-224-5p, hsa-miR-142-3p, hsa-miR-21-3p LINC01140 hsa-miR-142-3p, hsa-miR-21-3p LOC146880 hsa-miR-145-5p LOH12CR2 hsa-miR-106b-5p, hsa-miR-93-5p MBNL1-AS1 hsa-miR-106b-5p, hsa-miR-141-3p, hsa-miR-183-5p, hsa-miR-200a-3p hsa-miR-32-5p, hsa-miR-93-5p MEG3 hsa-miR-106b-5p, hsa-miR-22-5p, hsa-miR-429, hsa-miR-93-5p MIR100HG hsa-miR-183-5p MIR4697HG hsa-miR-141-5p, hsa-miR-205-5p, hsa-miR-22-5p MIR9-3HG hsa-miR-10b-5p, hsa-miR-139-5p, hsa-miR-140-5p, hsa-miR-143-5p, hsa-miR-195-5p, hsa-miR-320a MIR99AHG hsa-miR-106b-5p, hsa-miR-141-5p, hsa-miR-182-5p, hsa-miR-93-5p MST1P2 hsa-miR-328-3p NR2F1-AS1 hsa-miR-141-5p, hsa-miR-15b-5p, hsa-miR-185-5p, hsa-miR-22-5p, hsa-miR-425-5p OIP5-AS1 hsa-miR-143-5p RASA4CP hsa-miR-182-5p SMIM10L2B hsa-miR-15b-5p, hsa-miR-182-5p, hsa-miR-205-5p, hsa-miR-425-5p SNHG7 hsa-miR-182-5p, hsa-miR-200a-5p SYS1-DBNDD2 hsa-miR-16-5p TMPO-AS1 hsa-miR-143-3p TPTEP1 hsa-miR-141-3p, hsa-miR-142-3p, hsa-miR-16-5p ZNF876P hsa-miR-106b-5p, hsa-miR-15b-3p, hsa-miR-93-5p
CC, cervical cancer; lncRNA, long non-coding RNA. Table V) . For example two lncRNAs (MST1P2 and FTX) were differently expressed in CC patients of different race, five lncRNAs (LOH12CR2, GOLGA2P10, A2M-AS1, ATP1A1-AS1 and ACVR2B-AS1) were differently expressed at different pathological stage, ten lncRNAs (FAM66C, GOLGA2P5, ACV R 2B-AS1, Z N F876P, M I R9 -3HG, EM X 2OS, LINC00341, FLJ10038, ILF3-AS1 and AMZ2P1) were expressed differently depending on the tumor TNM stage, four lncRNAs (GOLGA2P5, ACVR2B-AS1, ZNF876P and MIR9-3HG) were differently expressed at different clinical stage, four lncRNAs (ILF3-AS1, GOLGA2P5, MIR9-3HG and FAM66C) were aberrantly expressed depending on the patient outcome assessment and four lncRNAs (SYS1-DBNDD2, MIR9-3HG, DDX12P, LINC00312) were differently expressed in high and low risk types of HPV infection (Table V) .
RT-qPCR verification and ROC.
In order to prove the reliability of the above bioinformatics analysis results from -5p  FBXO32  hsa-miR-381-3p  CACNA1C, ELK4, FOXO1, GABARAPL1, ZFPM2  hsa-miR-425-5p  AMPH  hsa-miR-429  CACNB2, DOCK4, E2F3, ELK4, ERG, GAB1, GTF2E1, GUCY1A3, MYB, RAB11FIP2, RUNX1,  ST3GAL2, TP73, ZEB1, ZFPM2  hsa-miR-497-5p  ACACA, ADCY5, AKT3, BCL2, CDC25A, CNTNAP1, E2F3, EPHA1, FGF2, FOXO1, FZD4, INSR,  ITGA10, KDR, MASP1, MYLK, NUP50, PTPRM, RAB11FIP2 , RECK, SGCD, SRPK1, WWC1, ZAK, ZYX hsa-miR-93-5p AKT3, BCL2L11, E2F1, E2F2, ELK4, ERBB3, FLT1, GAB1, GUCY1A3, KCNJ8, KCNMA1, KIF23, KPNA2, NR4A3, PGP, PPP1R12B, PTGER3, RBL1, RPS6KA2, RUNX1, SGCD, SLC2A4, SPG20, ST6GALNAC3, ST6GALNAC6, TBL1X, THRA CC, cervical cancer. TCGA, we random selected 11 key lncRNAs (DDX12P, GOLGA2P5, GOLGA2P10, LINC00467, MIR9-3HG, MST1P2, TMPO-AS1, EMX2OS, LINC00663, MEG3, SYS1-DBNDD2) and verified their actual expression levels in 31 pairs of newly diagnosed clinical samples. The results showed that seven lncRNAs were upregulation and four lncRNAs were downregulated in CC tumor tissues compared to adjacent normal cervical tissues. The validation results for these 11 key lncRNAs were with the above TCGA bioinformatics results. This showed that our bioinformatics analysis was accurate and reliable ( Fig. 6 and Table VI) .
We assessed the diagnostic value of specific lncRNAs and found that three out of six lncRNAs examined displayed good diagnostic values (Fig. 7) . ROC curve analysis revealed AUC values of 0.773, 0.723 and 0.724 for EMX20S, MEG3 and SYS1-DBNDD2, respectively (P<0.05; Fig. 7A ), which suggested that these lncRNAs may be good candidates for diagnostic biomarkers in CC because their AUC values exceeded 0.7. ROC analysis also showed an AUC value of 0.689 for MIR9-3HG (P<0.05; Fig. 7A ), while results for DDX12P and LINC00663 were not statistically significant (P>0.05; Fig. 7C ). The AUC of these four lncRNAs combined was 0.841, which was higher than that of the single lncRNA (P<0.05; Fig. 7B ).
Discussion
Despite improvements in treatment, early prevention and diagnosis remains the most effective way to reduce morbidity and mortality of CC (24) . With the extensive use of ThinPrep cytologic test (TCT) and HPV DNA screening techniques, the incidence and mortality rates of CC have declined over the past three decades, but the 5-year survival percentage of patients has still remained below 40% (4), and 85% deaths have occured in developing countries such as China (25) . Therefore, the identification and validation of biomarkers for early diagnosis and prognosis of CC is an important goal. Many studies have reported lncRNAs related to the biological regulatory functions in many cancers (26) . Abnormal expression of lncRNAs has also been widely detected in a variety of diseases (23, 27) . Dysregulated lncRNAs have now emerged as key players in the development of cancer. However, the expression profiles of lncRNA in CC have been described in only a few studies involving small sample size (28) . Furthermore, very few studies have examined the interaction between lncRNA, mRNA and miRNA in CC. Results from the few studies performed have showed that lncRNAs play an important function in ceRNA network, but their relationships to specific ceRNA networks are still unclear (29, 30) . Recently, a new ceRNA hypothesis was proposed in which lncRNAs play a regulatory role through the competitive binding of miRNAs (31, 32) . Based on this mechanism, Li et al constructed a ceRNA network related to oral squamous cell carcinoma (19) . With further study of ceRNA network, many researchers have showen that miRNAs regulated gens and interact with lncRNAs in the ceRNA network (33) . In our study, we first screened lncRNAs, miRNAs and mRNAs. The three types of non-coding RNA were related to FIGO clinical stage in CC from the TCGA database. As far as we know, this is the first time that lncRNA-miRNA-mRNA ceRNA networks have been established in CC. Based on clinical information and RNA sequencing profiles, we found that specific key lncRNAs from ceRNA network were altered in different CC clinical manifestations by. We further verified the expression level of 11 key lncRNAs in clinical samples by RT-qPCR.
We investigated aberrantly expressed mRNAs in CC intersection with RNAs from the three groups of RNA sequence data. The results of GO and pathway analysis also revealed potential regulatory relationship of mRNA related lncRNAs. The abnormal signaling pathways may play important roles in the development and progression of CC The GO results showed significant differences in cellular functions and transcription process. The KEGG pathway analysis showed that PI3K-Akt signaling pathway (34, 35) , p53 signaling pathway (36) , MAPK signaling pathway, and viral carcinogenesis were particularly important cancer-related pathways (37) .
An increasing number of studies have also showed that lncRNAs may bind to other transcription factors and are involve in regulating the ceRNA network (14, 38, 39) . For example, the lncRNA MEG3 is an important gene for the progression of many types of cancer including CC (40). MEG3 over-expression imposes another level of post-transcriptional regulation, whereas MEG3 over expression increase the expression of the miR-664 target gene, ADH4, through competitive sponging of miR-664. Therefore, the potential regulatiory function of lncRNA-miRNA-mRNA interactions may also act during CC development. Based on the above analysis, we built an lncRNA-miRNA-mRNA ceRNA network in CC through bioinformatics analysis. We found that particular lncRNAs may be associated with cancer. The lncRNAs such as MEG3, LINC00341 and LINC00663 (41-43) may therefore acted as potential molecular biomarker in other cancers, and may also be involved in the initiation and progression of cancer. Based on our research analysis, specific lncRNA was found to be indirectly related to mRNAs signaling pathways in ceRNA network of CC. The analysis results showed at leaet 10 pathways connected to cancer. Therefore, it is believed that these key lncRNAs may played an important regulatory role during CC formation. We analyzed the association of 42 key lncRNAs from the ceRNA network. The 19 key lncRNAs were related to clinical features. According to recent studies, these included the lncRNAs LINC00341 (42), FTX (44), LOH12CR2 (45) and LINC00312 (46) , which have been reported to be associated with prognosis in several cancers, while the function of other lncRNAs have not yet been reported. These lncRNAs, which were associated with clinical features, may have important research values in the development and prognosis of CC. We also uesed RT-qPCR to verify the expressions level of 11 key lncRNAs from the 31 pairs of newly obtained clinical samples. The result of RT-qPCR were consistent with the result of TCGA bioinformatics analysis, showing that it was basically reliable. The specificity and sensitivity of lncRNAs as a test indicator were then determined by ROC. Three lncRNAs (EMX20S, MEG3, SYS1-DBNDD2) had significant single diagnostic values, but more important, the AUC of the combined four lncRNAs (EMX20S, MEG3, SYS1-DBNDD2, MIR9-3HG) was 0.841 (P<0.05), which was greater than that any single lncRNA, suggested that the combined diagnosis could improve the diagnostic efficacy of CC.
In conclusion, we screened for key lncRNAs which related to CC from the large number of candidate lncrRNAs in the TCGA database by bioinformatics analysis and found differentially expressed lncRNAs associated with different clinical features. Importantly, we have constructed a ceRNA network which encompassed the lncRNA-miRNA-mRNA interactions in CC, and investigated the CC related key lncRNAs for their potential regulatory role. We also validated key lncRNAs expression levels by RT-qPCR and thus demonstrated the reliability and validity our bioinformatics analysis. Furthermore, we explored the diagnostic value of some these key lncRNAs. Our results suggested that these key lncRNAs may be new candidate biomarkers for the clinical diagnosis, classification and prognosis of CC. Due to sample size limitations of TCGA database. Preliminary analysis and screening was only a reference and exploration, our research focused on the follow-up study for the enlarged sample size of Chinese population. Future research studies will require molecular investigations and more clinical samples to verify the function and mechanism of these lncRNAs.
